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ABSTRACT
Inﬂammation is a major biological process regulating the interaction between organisms and the
environment, including the diet. Because of the increase in chronic inﬂammatory diseases, and in light of
the immune-regulatory properties of breastfeeding, the ability of dairy products to modulate
inﬂammatory processes in humans is an important but unresolved issue. Here, we report a systematic
review of 52 clinical trials investigating inﬂammatory markers in relation to the consumption of dairy
products. An inﬂammatory score (IS) was deﬁned to quantitatively evaluate this interaction. The IS was
signiﬁcantly positive for the entire data set, indicating an anti-inﬂammatory activity in humans. When the
subjects were stratiﬁed according to their health status, the IS was strongly indicative of an anti-
inﬂammatory activity in subjects with metabolic disorders and of a pro-inﬂammatory activity in subjects
allergic to bovine milk. Stratifying the data by product categories associated both low-fat and high-fat
products, as well as fermented products, with an anti-inﬂammatory activity. Remarkably, the literature is
characterized by a large gap in knowledge on bioavailability of bioactive nutrients. Future research should
thus better combine food and nutritional sciences to adequately follow the fate of these nutrients along






Immunity is a major process among the biological phenomena
regulating the interaction of higher organisms with the envi-
ronment, in particular as it provides a mechanism by which
external agents are either rejected (e.g., phagocytosis of patho-
gens) or internalized (e.g., oral tolerance to ingested food) by
the organism. One main expression of the immune system is its
ability to mount an inﬂammatory reaction to these stimuli. If
sustained, the inﬂammatory response may, however, turn
against the host’s own tissues, leading to a range of chronic
inﬂammatory diseases that have now supplanted infectious dis-
eases worldwide (Hunter and Reddy, 2013). The Global Busi-
ness Intelligence Research estimated the global inﬂammatory
therapeutics market to reach $85.9 billion in 2017 (Global
Business Intelligence Research, 2011).
Most chronic inﬂammatory diseases (e.g., obesity, diabetes)
as well as allergic diseases are strongly inﬂuenced by nutrition,
the metabolism of food being intimately associated with inﬂam-
matory processes (Hotamisligil, 2006). In addition,
postprandial inﬂammation is part of the normal stress reaction
of the cell in response to the ingestion of food (Hernandez-
Aguilera et al., 2013). Nutrients thus appear to be able to modu-
late the inﬂammatory status of humans and inﬂammation has
consequently emerged as an important research topic in food
and nutrition sciences (Calder et al., 2011; Calder et al., 2013;
Klop et al., 2012).
Dairy products represent a particularly interesting food
type to study in the context of inﬂammation. From an evo-
lutionary point of view, ancestors of mammalians may have
possessed primitive apocrine-like glands in the skin, approx-
imately 310 million years ago, that incorporated elements of
the innate immune system in providing protection to the
skin and to eggs that were moistened (Oftedal, 2012).
Because of its ability to support the development of the
immune system of the infant, to inhibit bacterial growth
(e.g., lactoferrin) and to deliver anti-oxidative protection
(e.g., vitamins or glutathione), the potential of maternal
milk to inhibit inﬂammation in the offspring has
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consequently raised interest (Lepage and Van de Perre,
2012). Part of these properties may be maintained when
boundaries across species and life cycles are crossed, i.e. in
the context of the consumption of dairy products by human
adults (Labonte et al., 2013). In addition, the importance of
food in modulating the gut microbiota, a key regulator of
immunity, has become more evident during the last decade
(Kau et al., 2011). Milk is a natural and culturally accepted
vector to deliver supplements to the human organism
(Ceapa et al., 2013), in particular prebiotic and probiotics
that both modulate the microﬂora and thus inﬂuence
immune and inﬂammatory processes. Besides, milk is ame-
nable to a wide range of technological transformations,
including its fermentation by lactic acid bacteria to produce
fermented dairy products such as yoghurt or cheese whose
metabolites may further modulate the ability of milk to
inﬂuence immune processes in humans (Augustin and Uda-
bage, 2007). Milk and dairy products are major food prod-
ucts in human nutrition, amounting to 14% of the caloric
intake in developed countries (FAO, 2013b). The Food and
Agriculture Organization (FAO) forecasted a world milk
production of 784 million tons in 2013 (FAO, 2013a),
which amounts to an average of circa 100 L milk per year
per human being. An evaluation of the ability of dairy
products to modulate inﬂammatory processes in humans is,
thus justiﬁed.
Studies addressing the impact of dairy products on
inﬂammatory processes present a contradictory landscape.
Indeed, dairy products were reported to be beneﬁcial, inac-
tive, as well as detrimental. For illustration, the ATTICA
study reported an inverse relationship between the con-
sumption of dairy products and markers of the metabolic
syndrome, including the inﬂammatory markers associated
with this syndrome (Panagiotakos et al., 2010). On the
other hand, the relatively high concentrations of saturated
fat and dietary antigens in cow milk have raised concern
and some scientists claimed that dairy products are a major
cause in the development of chronic inﬂammatory disorders
and autoimmune diseases (Melnik, 2009). These opposite
statements reﬂect the wide spectrum of information avail-
able in the scientiﬁc literature on the relationship between
the consumption of dairy products and inﬂammation.
Indeed, many articles have been published on this relation-
ship, but systematic reviews are scarce (Labonte et al.,
2013) and incomplete. The association between the con-
sumption of dairy products and inﬂammation in humans,
thus merits clariﬁcation for the following reasons: (i) milk
and dairy products play qualitatively and quantitatively an
important role in human nutrition (Haug et al., 2007); (ii)
inﬂammation, in particular low-grade systemic inﬂamma-
tion, has a signiﬁcant impact on human health and longev-
ity (Candore et al., 2010); (iii) nutrient metabolism and
inﬂammation are mechanistically closely interconnected
(Hotamisligil, 2006; Calder et al., 2011; Klop et al., 2012;
Calder et al., 2013; Hernandez-Aguilera et al., 2013).
The property of the foods investigated in human nutritional
trials are often poorly documented what renders an objective
evaluation of the clinical outcome very difﬁcult. This review
aimed to narrow the gap between food science and nutritional
science. The information usually provided by reviews on medi-
cal topics (Moher et al., 2009) was thus complemented with
product-related information that is usually requested by regula-
tory authorities to document the functional properties of the
food products and nutrients of interest (EFSA Panel on Dietetic
Products Nutrition and Allergies, 2011; FDA Ofﬁce of Nutri-
tion Labeling and Dietary Supplements, 2009).
The speciﬁc goals of this review are to:
 Present a structured overview of published original
human studies investigating the impact of the consump-
tion of dairy products on inﬂammatory processes;
 Develop a method to quantitatively evaluate the results
extracted from these studies;
 Use this method, in order to evaluate whether pro- or
anti-inﬂammatory properties of dairy products can be
concluded from these studies;
 Identify research gaps that should be ﬁlled to allow a bet-
ter evaluation of the anti- or pro-inﬂammatory properties
of speciﬁc dairy products in speciﬁc human populations.
Methods
Literature search strategy
A review was conducted using Medline and Scopus search that
includes all original research articles written in English, pub-
lished since January 1990, on the relationship between inﬂam-
matory markers and the consumption of dairy products in
humans.
A ﬁrst Medline search was conducted on February 13, 2013.
A search of the Scopus database was also conducted on June
18, 2013 and the entries not identiﬁed in Medline were
included into the evaluation. Medline and Scopus were
searched again on December 10, 2013 to identify and include
additional articles published until November 30, 2013. The
search strategies were as follows:
 Medline search strategy. (milk OR cheese OR yog OR
dair) AND inﬂam NOT (“breast milk” NOT “human
milk”) NOT review. Filters: Case Reports; Clinical Trial;
Clinical Trial, Phase I; Clinical Trial, Phase II; Compara-
tive Study; Controlled Clinical Trial; Multicenter Study;
Randomized Controlled Trial; Evaluation Studies; Meta-
Analysis; Systematic Reviews; Humans; English;
 Scopus search strategy. (((TITLE-ABS-KEY(milk OR cheese
OR yog OR dair) AND TITLE-ABS-KEY(inﬂam) AND
NOT TITLE-ABS-KEY(“breast milk” not “human milk”))
AND DOCTYPE(ar)) AND (humans)) AND (inﬂamma-
tion) AND (LIMIT-TO(LANGUAGE,”English”)).
Data collection process
Figure 1 shows the ﬂow diagram with the ﬁve phases leading to
the quantitative analysis of the 52 clinical studies. Seventy-eight
study results were extracted from these clinical studies to mea-
sure the impact of dairy products on inﬂammation in humans.
Phase 1. For phase 1, all studies identiﬁed by the search
strategy were randomly split into six groups. Each group of
studies was distributed to reviewers of one partner institution.
Based on title and abstract, only studies that were clearly
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associated with inﬂammatory mediators and with the ingestion
of dairy products (i.e., milk, cheese, yoghurt, fermented milk,
whey products, and other dairy foods) by humans, were kept
for phase 2 of the review process. Studies investigating human
milk and/or breastfeeding, were excluded. Studies in which
dairy products were used as a vector to deliver ingredients such
as probiotics, prebiotics or bioactive nutrients such as vitamins
or peptides, were excluded. However, studies were included if
non-supplemented dairy products were used as control prod-
ucts and if information was available on the impact of these
control products on inﬂammatory markers compared to the
baseline values (e.g., comparison before and after treatment).
Studies investigating isolated dairy proteins or lipids, were
excluded. The information derived from the abstracts and the
titles was summarized in tabulated form (see section “Tabu-
lated summary” below) and used for selecting the studies to be
evaluated in phase 2 of the review.
Phase 2. The studies retained, based on their abstracts, were
again randomly split into six groups and each group of studies
was distributed to reviewers of one partner institution. The tab-
ulated summary was completed, based on the content of the
articles. A workshop took place in Lisbon on June 4–6, 2013
during which the reviewers presented an overview of their eval-
uation of the studies. Based on these presentations the content
and form of the tabulated summary were reﬁned.
Phase 3. The study results were grouped into ﬁve sub-
ject categories (see section “Tabulated summary” below)
and each group of studies was accordingly redistributed to
the reviewers of one partner institution. The studies were
re-evaluated to ﬁnalize the content of the tabulated sum-
mary. Finally, a non-systematic search of the literature
was conducted by the reviewers, for each of the ﬁve sub-
ject categories, to identify human studies that may not
have been identiﬁed by the previous searches. The form of
the complementary search strategy was left to the discre-
tion of the reviewing authors and no additional studies
were identiﬁed.
Phase 4. The tabulated summary of all studies was
ﬁnally revised by two reviewers from one institution, in
order to harmonize its content. In particular, the status of
each column in the tabulated summary was changed from
the description of one clinical study per column to the
description of one study result per column. This
adaptation was motivated by the fact that several studies
reported results for more than one dairy product or more
than one subject category, each of these study results
needing a separate evaluation.
Phase 5. A quantitative estimation of the ability of dairy
products to modulate inﬂammation was conducted, for each
study result, based on the content of the tabulated summary
and on the establishment of the inﬂammatory score (IS) (see
the next two sections).
Tabulated summary
The tabulated summary was not only deﬁned in broad com-
pliance with the reporting of systematic reviews according
to the PRISMA checklist (Moher et al., 2009), but also inte-
grated elements requested by regulatory authorities for the
preparation of applications on health claims (EFSA Panel
on Dietetic Products Nutrition and Allergies, 2011; FDA
Ofﬁce of Nutrition Labeling and Dietary Supplements,
2009). The tabulated summary contains the following
descriptors:
Reference—Presents the bibliographic reference of the clini-
cal trial from which each study result was extracted. Studies for
which more than one study result was extracted are indicated
and the study results are numbered.
Subject category—The articles are grouped into ﬁve catego-
ries based on the clinical status of the subjects enrolled in the
selected studies:
 HEALTH, for studies investigating healthy subjects;
 MET, for studies on subjects with metabolic and cardio-
vascular disorders, including obesity and overweight;
 GIT, for studies enrolling subjects with non-allergic gas-
trointestinal disorders;
 HYPER, for studies with subjects suffering from food
hypersensitivity, in particular allergy to dairy products,
but not from lactose intolerance;
 OTHERS, for studies describing subjects with all other
disorders, in particular lung disease, joint disease, and
infection.
Articles discussing both gastrointestinal disorders and food
hypersensitivity are included in the category HYPER.
Target indication—Potential health beneﬁt, clinical indica-
tion, or safety issue investigated in the study.
Figure 1. Flow diagram of the ﬁve phases conducted to establish an IS for the 78 study results extracted from the 52 human studies in which the impact of dairy products
on inﬂammation was investigated.
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Target population—Population targeted by the target
indication.
Fat content—The dairy product investigated is categorized
as ‘high-fat’, ‘low-fat’, or, otherwise, “not available (n.a.)”. The
classiﬁcation between high-fat and low-fat dairy products was
made based on the information given in the corresponding
paper. When the authors did not mention the fat content of the
investigated product or when they did not use special terminol-
ogy such as “fat-reduced, skimmed, semi-skimmed, high-fat,
normal-fat,” the study product was classiﬁed as “n.a.”.
Fermentation—The dairy product investigated is catego-
rized as “fermented,” “non-fermented,” or, otherwise, “n.a.”.
Test and control products—Details on the foods used as
test or control products (dairy or non-dairy) are reported.
Only studies using dairy food products as the test or the
control product are considered. For studies with more than
one dairy product investigated, each dairy product is
reported as a separate study result (one column for each
product).
Test and control subjects—For each group enrolled in the
study as test or control subjects, the number of subjects in the
group, their gender (if available), age (including range) and
health or disease status is provided (if appropriate). For studies
with more than one group of subject investigated, each group is
reported as a separate study result (one column for each
group).
Diet—The composition of the dairy products investigated,
its quantity, and the duration of the dairy products consump-
tion during the study period is reported.
Controlled dairy test—Studies that are controlled and in
which a dairy product is the test product are labeled as “yes,”
otherwise as “no”.
Randomization—Studies that are randomized are labeled as
“randomized,” otherwise either “non-randomized” or “n.a.”.
Time factor—The studies are categorized as either “longitu-
dinal” or “cross-sectional”.
Study results—The study results are generally expressed by
presenting the food products investigated, the inﬂammatory
markers measured, and the direction of the effect. Depending
on the study design, seven different types of outcome are
presented:
 Outcome 1 [Dairy vs Control], when dairy products are
the test products and compared against control products;
 Outcome 2 [Dairy (end time vs baseline)], when dairy
products at baseline are compared under fasting condi-
tions over several days (dn vs d0), weeks (wn vs w0), or
months (mn vs m0);
 Outcome 3 [Dairy (xh vs 0h)], when dairy products at
baseline are compared over several hours in challenge
postprandial studies (nh vs 0h);
 Outcome 4 [Dairy (test subjects vs control subjects)], for
studies in which the effects of dairy products are com-
pared in two populations of subjects;
 Outcome 5 [Dairy : Correlation], for studies in which the
consumption of dairy products is quantitatively corre-
lated to inﬂammatory markers. If available, adjustments
for confounders are indicated;
 Outcome 6 [Dietary pattern 1 vs Dietary pattern 2], for
studies in which the relative impact on inﬂammation of
different dietary patterns containing dairy products is
evaluated;
 Outcome 7 [Dietary patterns : Correlation], for studies in
which dietary patterns containing dairy products are cor-
related with inﬂammatory markers. If available, adjust-
ments for confounders are indicated.
The type of outcome (1–7) is indicated for each study result.
The strength of the effects was expressed by the direction of
the statistically signiﬁcant change in the inﬂammatory signal
(!: no statistically signiﬁcant effect; ": statistically signiﬁcant
increase; #: statistically signiﬁcant decrease) or of the correla-
tions (corr!: no statistically signiﬁcant correlation; corr": sta-
tistically signiﬁcant positive correlation; corr#: statistically
signiﬁcant negative correlation). The criteria for statistical sig-
niﬁcance are indicated as reported in each study but are not
documented in this review. To avoid bias, care was taken to
document all results obtained with the inﬂammatory markers,
including results in which no statistically signiﬁcant changes
were observed. Inﬂammatory markers are shown in italics in
the table if their increase are associated with an anti-inﬂamma-
tory effect.
Net change in inﬂammatory markers—The inﬂammatory
markers shown in Table 1 were considered for inclusion in this
review. This list was extracted from recently published work
that compiles a comprehensive list of inﬂammatory markers
reported in nutritional studies (Calder et al., 2013). It offered
clear harmonizing criteria for inclusion or exclusion of the IS
that were evaluated by each reviewer. The net change in inﬂam-
matory markers was calculated for each study result by sum-
ming up the changes in all inﬂammatory results measured. A
value of ¡1 was attributed for each change in inﬂammatory
parameters contributing to a pro-inﬂammatory status (e.g., an
increase in a pro-inﬂammatory parameter or a decrease in an
anti-inﬂammatory parameter). A value of C1 was attributed
for each change in inﬂammatory parameters contributing to an
anti-inﬂammatory status (e.g., a decrease in a pro-inﬂamma-
tory parameter or an increase in an anti-inﬂammatory parame-
ter). A value of 0 was attributed for study results in which the
inﬂammatory markers did not change. None of the 78 study
results for which the net change in inﬂammatory markers was
measured provided results in which both anti- and pro-inﬂam-
matory changes were observed together.
Sustainability of effect over time—This line reports
whether sustainability of the inﬂammatory effect over time
was “investigated,” “discussed,” or “not discussed”. A study
result investigating and reporting a maintenance of the
inﬂammatory effect after a washout phase of at least one
week is labeled “yes”.
Dose-response—This line reports whether a dose-response
relationship was investigated (yes) or not (no). If yes, a short
description is presented.
Bioavailability data—Label as “yes” if information is pro-
vided on bioavailability of dairy product components, other-
wise label as “no”. In cases where bioavailability data was
obtained in the study (yes), a short presentation of the informa-
tion is presented in the table.
Biological plausibility—This line presents whether the
mechanism of action by which the dairy constituents exert
their anti- or pro-inﬂammatory effects was discussed or
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investigated. The mechanism of action is shortly
presented.
Bioactive components—If discussed or investigated, the
components of the dairy products considered as responsible for
the anti- or pro-inﬂammatory effect are shortly presented.
Clinical evidence—If available, this line presents the results
of clinical endpoints that, if changed, contribute to an upgrad-
ing of the overall effect. The list of clinical endpoints includes:
non-systemic inﬂammatory markers (such as, cellular, organ
inﬂammation, joint pain, ﬂare), parameters formally recognized
as being associated with the metabolic syndrome including
changes in triglycerides, HDL cholesterol, blood pressure,
plasma glucose, insulin tolerance, BMI, waist circumference,
glucose tolerance, insulin resistance, waist:hip ratio, urinary
albumin excretion, albumin:creatinine ratio, markers of oxida-
tive stress known to promote inﬂammation and other clinical
endpoints such as mortality or cardiovascular events.
Financing of research—This line mentions how the study
was supported ﬁnancially and is labeled as either “public”, “pri-
vate”, “private and public”, or “not presented”.
Grading criteria—This line presents the grading criteria
used to calculate the IS according to Table 2. The label “None”
is attributed a value of 0, indicating a study result in which no
net change in inﬂammatory markers was measured. The label
“Anti” is attributed a value of C1, indicating a study result with
a positive net change in inﬂammatory markers. The label “Pro”
is attributed a value of ¡1, indicating a study result with a neg-
ative net change in inﬂammatory markers. For study results
with a net change in inﬂammatory markers different from zero,
the labels “Anti” and “Pro” are completed with the numbers 1–
11 indicating which one of the quality criteria presented in
Table 2 were met. These criteria could be retrieved from the fol-
lowing descriptors in the tabulated summary: (1) “controlled
dairy test”, (2) “randomization”, (3) “time factor”, (4) “test





2-Arachidonoylglycerol Lung function in response to indirect challenge (Allergic asthma)
5-HETE LXA4
5-HPETE Lyso-PA
a-1-Antichymotrypsin Macrophages (total count, tissue inﬁltration, CD163C, CD68C, S100C)
a-1-Antitrypsin MAPK, activated (Crohn’s disease)
Ab42, increased (Alzheimer’s disease) MaR1
Adiponectin, low (obesity, type 2 diabetes) MCP-1 (CCL2)
Anandamide Microglia, activated (Alzheimer’s disease)
Antimicrobial antibodies (Crohn’s disease) MIP-1a (CCL3)
Antimicrobial peptides MIP-2a (CXCL2; GROb; GRO-2)
Astrocytes, reactive (Alzheimer’s disease) Monocytes (total count, CD66b, CD11c)
Autoantibodies Neutrophils (total count, tissue inﬁltration, CD11b)
B lymphocytes (total count) NF-kB (Crohn’s disease)
Basophils, mast cells (total count, tissue inﬁltration) NO (cardiovascular diseases)
Calprotectin (Crohn’s disease) Osteopontin (Allergic asthma)
Complement C3 (C3) PAF
Complement C4 (C4) PD1 (NPD1)
CPN60 (Crohn’s disease) PGD2
CRP PGD3
Cysteinyl-LT (Allergic asthma) PGE1
Eicosanoids (Rheumatoid arthritis) PGE2
Eosinophilic cationic protein (Allergic asthma) PGE3
Eosinophils (total count, tissue inﬁltration, CD11b) PGF2a
Eotaxin (Allergic asthma) PGI2
E-selectin (CD62E) PKR (Crohn’s disease)
Fibrinogen Plasminogen activator inhibitor-1 (PAI-1)
GRP78 (Crohn’s disease) P-selectin (CD62P)
ICAM-1 (CD54) RANTES (CCL5)
IFN-g Rheumatoid factor (Rheumatoid arthritis)
IgE, total and allergen speciﬁc (Allergic diseases) RvD1
IL-10 RvE1
IL-12 (IL-12A or p35 or IL-12B or p40 heterodimeric) S100 proteins (S100A12, S100A8/A9) (Crohn’s disease)
IL-13 (Allergic asthma) Serum amyloid A (SAA)
IL-17A SMAD7 (Crohn’s disease)
IL-18 Sphingosine-1-phosphate
IL-1b sPLA2
IL-1ra T lymphocytes (total count, tissue inﬁltration)
IL-23 (IL-23A or p19 or IL-12B or p40 heterodimeric) Tau, total (Alzheimer’s disease)
IL-4 (Allergic asthma) TNF-a
IL-5 (Allergic asthma) TNFR (TNFR1 and TNFR2)
IL-6 tPA
IL-8 (CXCL8) Tryptase (Allergic asthma)
Inﬂammatory gene expression, cytokine expression (Obesity) TXA2
IP-10 (CXCL10) VCAM-1 (CD106)
Leptin VEGF (Psoriasis)
Leucocytes (WBC) (total count, tissue inﬁltration) von Willebrand factor (vWF)
1The markers are listed in alphabetical order. Adapted from (Calder et al., 2013).
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product” or “control product”, (5) “study results” and “net
change in inﬂammatory marker”, (6–7) “study results”, (8)
“sustainability of effect over time”, (9) “dose-response”, (10)
“biological plausibility” or “bioactive components”, (11) “clini-
cal evidence”.
IS—The IS is the sum of the criteria reported above. Study
results in which all criteria are fulﬁlled could thus theoretically
reach an IS of ¡12 for results indicating a pro-inﬂammatory
activity of dairy products and an IS ofC12 for results indicating
an anti-inﬂammatory activity of dairy products. Study results
with an initial IS of 0 could not be modiﬁed by these criteria
and the ﬁnal IS thus remained 0, independently of the quality
of the clinical study.
Table S1 provides an example of the calculation of the IS for
one study result.
Determination of the IS for groups of study results
A median IS was calculated for the entire data set as well as for
the following categories of study results:
 Subjects category (HEALTH, MET, GIT, HYPER);
 Fat content of dairy product (low-fat, high-fat);
 Fermentation status of dairy product (non-fermented,
fermented).
Non-parametric statistics were conducted to analyze the
data (signiﬁcance level: p<0.05). The two-sided Wilcoxon
Signed-Rank test was conducted to identify whether the median
IS of the selected categories were statistically different from zero
(H0: median ISD0; Ha: median IS 6¼0). A mean IS>0 indicated
an anti-inﬂammatory effect whereas a pro-inﬂammatory effect
was indicated by a mean IS<0. The Kruskall-Wallis test was
conducted to identify difference in the mean IS between differ-
ent categories of study results.
Results
Tables 3–5 show the tabulated summary of the 78 study results
extracted from the 52 human studies retained for this review.
Each table contains 25 descriptors covering a wide range of
study characteristics including, amongst others, a description
of the enrolled subjects, the test and control products, the study
designs, and the IS (documented in the last line). Table 3 shows
the data for study results with a positive IS, i.e., for results
indicative of an anti-inﬂammatory effect of dairy products.
Table 4 shows the data for study results with a negative IS, i.e.,
for results indicative of a pro-inﬂammatory effect of dairy
products. Finally, Table 5 shows the data for study results with
an ISD0, i.e., for results with no modulation of inﬂammatory
processes by dairy products.
Figure 2 shows the overall distribution of the data obtained
for each of the inﬂammatory markers listed in Table 1, that
were measured at least once in the set of 78 study results
reviewed. Out of the 98 inﬂammatory markers listed in Table 1,
57 markers were investigated at least once (58%). A total of 309
observations were reported with these inﬂammatory markers,
131 (42%) being accounted for by three cytokines, i.e., CRP (51
observations), IL-6 (44 observations), and TNF-a (36 observa-
tions). For each of these cytokines, the number of observations
reporting no effect was the highest (CRP: 34 out of 51; IL-6: 26
out of 44; TNF-a: 23 out of 36) followed by the observations
reporting an anti-inﬂammatory effect (CRP: 16 out of 51; IL-6:
15 out of 44; TNF-a: 11 out of 36). The number of these obser-
vations reporting a pro-inﬂammatory effect was the lowest for
all three cytokines (CRP: 1 out of 51; IL-6: 3 out of 44; TNF-a:
2 out of 36). The only parameter systematically pointing to the
pro-inﬂammatory state was ‘eosinophil count’ (5 out of 5), a
parameter that was exclusively measured in studies investigat-
ing subjects with milk allergy and thus categorized in the sub-
ject category HYPER.
Taking into account the quality of all studies reviewed in the
present article, we have developed a quantitative method that
calculates an IS based on the range of eleven criteria listed in
Table 2. Figure 3 presents the results of this analysis. Panel A
ﬁrst illustrates the number of study results identiﬁed with evi-
dence for an anti-inﬂammatory activity (32 study results), a
pro-inﬂammatory activity (19 results), or no change in inﬂam-
matory activity (27 study results). Panel B shows a distribution
of the IS calculated for each of these study results, according to
the criteria presented in Table 2. Although both panels in
Figure 3 illustrate that the study results are well distributed
among all three categories (anti-inﬂammatory, no effect, pro-
inﬂammatory), the data indicating an anti-inﬂammatory activ-
ity appear to prevail over data pointing to a pro-inﬂammatory
activity. This observation was conﬁrmed by the positive mean
IS for the set of 78 study results and the rejection of the null
hypothesis for the median IS in the two-sided Wilcoxon
Signed-Rank test, indicating an anti-inﬂammatory activity of
dairy products (Table 6).
When the results were stratiﬁed according to subject catego-
ries, differences in the distribution of the study results appeared
between these categories (Figure 4). The group of 37 study
results investigating healthy subjects, was characterized by
study results covering each of the three possible effects (anti-
inﬂammatory, no effect, pro-inﬂammatory). On the other
hand, the group of 24 study results investigating subjects with
metabolic disorders, including healthy obese subjects, was char-
acterized by a lack of data pointing to a pro-inﬂammatory
effect. The groups of study results investigating subjects with
Table 2. Criteria used to establish the IS to quantitatively evaluate the impact of
dairy products on inﬂammatory processes in humans.
Initial grading
a Grade 0 for a null net change in inﬂammatory markers (‘None’)
b GradeC1 for a positive net change in inﬂammatory markers (‘Anti’)
c Grade¡1 for a negative net change in inﬂammatory markers (‘Pro’)
Cumulative upgrade of IS towards positive (C1) or negative (¡1) values
1 Controlled study (product or subject) with dairy test as a test product
2 Randomized study
3 Longitudinal study
4 The dairy product is not solely measured as part of a dietary pattern
5 2 inﬂammatory markers are changed
6 At least one inﬂammatory marker is measured in vivo (and not ex vivo)
7 The change in inﬂammatory marker is measured over 12h, e.g. not
postprandially
8 The effect is still measured after washout period of at least one week
9 A dose-response is demonstrated with the dairy product
10 Bioactive molecules or the biological plausibility have been convincingly
investigated
11 A clinical endpoint is changed that can be related to a metabolic
dysregulation associated with inﬂammation














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2508 A. BORDONI ET AL.
gastrointestinal disorders (8 study results) and of subjects with
allergy to dairy products (6 study results) lacked study results
indicative of an anti-inﬂammatory effect.
These observations were statistically conﬁrmed by compar-
ing the distribution of the IS for the groups of study results
investigating healthy subjects and subjects with metabolic dis-
orders (Table 6). Both mean IS were positive and the null
hypothesis for the median IS in the two-sided Wilcoxon
Signed-Rank test was rejected, pointing to an anti-inﬂamma-
tory activity of dairy products in these two subject categories.
The mean IS of the MET subject category were higher than for
the HEALTH subject category, but the Kruskal-Wallis test did
not point to a statistically signiﬁcant difference in the median
IS between both subject categories. The mean IS for the GIT
subject category was negative, but the Wilcoxon Signed-Rank
test on the median IS did not point to a statistically signiﬁcant
effect. However, the mean IS for the HYPER subject category
was negative and the null hypothesis for the median IS in the
two-sided Wilcoxon Signed-Rank test was rejected, indicating a
pro-inﬂammatory effect of dairy products in subjects allergic to
dairy products. Finally, a group of studies in which the subjects
could not be attributed to any of the above categories, had a
median IS that was statistically not different from zero.
In order to investigate the impact of dairy product process-
ing, in particular fat processing and fermentation on the IS, the
study results were stratiﬁed according to the fat content and
fermentation status of the dairy products investigated.
Thirty-ﬁve study results with high-fat dairy products and 20
study results with low-fat products were reported (Figure 5). In
contrast to the high-fat products, none of the study results with
low-fat products indicated a pro-inﬂammatory activity. The
mean IS of the low-fat product category was, indeed, lower
than for the high-fat product category but the Kruskal-Wallis
test on the median IS did not demonstrate this difference to
reach statistical signiﬁcance (pD0.083). However, the mean IS
of each product category was positive and the null hypothesis
for the median IS in the two-sided Wilcoxon Signed-Rank test
was rejected, indicating an anti-inﬂammatory activity for both
low-fat and high-fat dairy products (Table 6).
Thirty-three study results could be identiﬁed in which non-
fermented dairy products were investigated, whereas 16 study
results were reported with fermented products (Figure 6). The
mean IS of both the non-fermented and fermented product cat-
egory were positive, but the two-sided Wilcoxon Signed-Rank
test on the median IS only indicated a signiﬁcant anti-inﬂam-
matory activity for the fermented product category (Table 6).
In an attempt to identify the bioactive nutrients potentially
modulating inﬂammation, and to complement the human data
with preclinical data, we conducted a non-systematic and
non-quantitative evaluation of the literature available on the
inﬂammatory properties of dairy products in animal models
(unpublished data). Most of these studies reported an anti-
inﬂammatory effect; however, due to the different animal mod-
els and protocols used in the selected articles, it was not possi-
ble to compare results and to perform an analysis as we did for
human studies. It was anyway clear that the importance of
identifying the molecule(s) responsible for the effect, and its
mechanism of action, is poorly considered in animal studies,
too.
Discussion
Pro- and ant-inﬂammatory properties of dairy products
Overall, the IS of the entire data set composed of 78 study
results, extracted from 52 human studies indicates that the con-
sumption of dairy products is associated with anti-inﬂamma-
tory properties in humans. We qualify this association as weak,
although signiﬁcant, because the IS has a low magnitude that is
indicative of a low level of conﬁdence in the effect estimate.
By stratifying the study results according to the health status
of the enrolled subjects, we identiﬁed a pro-inﬂammatory activ-
ity of dairy products in subjects with milk allergy. This result is
mechanistically expected, as hypersensitive reactions can obvi-
ously be linked to the pro-inﬂammatory state (Savilahti and
Westerholm-Ormio, 2004). We therefore conclude that the IS
is an adequate tool to evaluate the impact of food and dietary
patterns on inﬂammation.
A systematic review recently assessed eight randomized con-
trolled nutritional intervention studies, which have investigated
the impact of dairy product consumption on biomarkers of
inﬂammation in overweight and obese adults (Labonte et al.,
2013). The authors concluded that the consumption of dairy
products did not exert adverse effects on biomarkers of inﬂam-
mation in these subjects, and that limitations among these
studies did not allow for the differentiation between a beneﬁcial
or neutral impact of dairy products on inﬂammation. In our
review, stratifying the data according to the health status of the
subjects, allowed us to identify 24 study results in the MET sub-
ject category. The IS of this data set indicates an anti-inﬂamma-
tory property of dairy products in subjects with metabolic
disorders. Noteworthy, the signiﬁcantly positive IS was also
indicative of an anti-inﬂammatory effect of dairy products in
the HEALTH group. We found, however, a trend towards a
higher IS in the MET group, compared to the HEALTH group
suggesting a stronger evidence for an anti-inﬂammatory activ-
ity of dairy products in the former subject category. This ﬁnd-
ing is illustrated by the identiﬁcation of ten studies reporting a
pro-inﬂammatory activity of dairy products in the HEALTH
group, whereas the MET group is the only category in which
none of the studies reported a pro-inﬂammatory activity of
dairy products. The speciﬁc reactivity of the MET group may
be linked mechanistically to the inﬂammatory nature of obesity.
Obesity is associated with a low-grade systemic chronic inﬂam-
matory state, characterized by the abnormal production of
inﬂammatory cytokines (Guri and Bassaganya-Riera, 2011;
Schwander et al., 2014). As low-grade systemic inﬂammation
links obesity to metabolic pathologies, including insulin resis-
tance, cardiovascular diseases, or type-2 diabetes, targeting obe-
sity-related inﬂammatory components may be a useful
preventive strategy. Low-grade chronic inﬂammation is modu-
lated by nutrients such as fatty acids, glucose, bioactive plant
compounds, vitamins and minerals, which either enhance or
alleviate the inﬂammatory state (Hirai et al., 2010). In this con-
text, as obese subjects are characterized by low-grade systemic
inﬂammation, the MET group may be more prone to the anti-
inﬂammatory action of dairy products than metabolically
healthy subjects.
Stratifying the data according to categories of dairy prod-
ucts, revealed an anti-inﬂammatory activity for both low-fat
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CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 2519
and high-fat dairy products. The IS indicated an anti-inﬂam-
matory activity of high-fat dairy products despite the fact that
nine studies were identiﬁed in which these products were asso-
ciated with a pro-inﬂammatory activity. The pro-inﬂammatory
activity identiﬁed with high-fat dairy products in these studies
was mainly attributed to the presence of saturated fat. Fat con-
sumption, in particular saturated fat (Steinberg, 2005) and
trans-fatty acids (Micha and Mozaffarian, 2009), has been asso-
ciated with inﬂammatory processes in humans. However,
recent opinions in nutrition research advocate that the adverse
health effects formerly associated with saturated fats, were
most likely due to other factors (Lawrence, 2013). The positive
IS, calculated for the high-fat products, is thus in line with this
reevaluation of the impact of fat consumption on human
health. Additionally, as both low-fat and high-fat products
were associated with a positive IS, the molecules with a poten-
tial anti-inﬂammatory activity in milk may cover a broad range
of nutrients, including polyunsaturated fatty acids (German
and Dillard, 2006), proteins (Chatterton et al., 2013), and gly-
cans (Newburg, 2013).
The IS of the product category “fermented dairy products”
indicates a beneﬁcial anti-inﬂammatory contribution, possibly
resulting from the bacteria present in dairy products or their
metabolic activity. The anti-inﬂammatory activity of strains of
lactic acid bacteria and biﬁdobacteria has indeed been reported
(Lomax & Calder, 2009;Tsai et al., 2012). The recent awareness
of the role of the gut microbiota in the modulation of the
immune system (Hakansson and Molin, 2011), further raises
interest in the integration of bacteria with anti-inﬂammatory
properties into dairy products (Dunne et al., 2001). Moreover,
products deriving from the fermentation of milk with bacteria,
in particular bioactive peptides (Ceapa et al., 2013) and glycans
(Newburg, 2013), which both interact with gut microbes or
immune cells, may contribute to an anti-inﬂammatory activity
of dairy products.
Research gaps
Our review also aimed at identifying research gaps preventing a
comprehensive understanding of inﬂammatory processes in
food and nutrition sciences. In particular, we have identiﬁed
the following gaps:
No consensus is available yet which clearly deﬁnes clinically
relevant inﬂammatory markers. For illustration in Europe, the
EFSA was required, following a consultation of stakeholders, to
give guidance on potential markers of inﬂammation. In its
response, the EFSA stated that “for function claims referring to
reduction of inﬂammation, a change in markers of inﬂammation
such as various interleukins does not indicate a beneﬁcial physi-
ological effect per se, but should be accompanied by a beneﬁcial
physiological or clinical outcome” (EFSA Panel on Dietetic
Products, 2011). This position is an important challenge to the
food and nutrition research community, given the difﬁculties
associated with the identiﬁcation of validated clinical markers of
disease reduction by dietary interventions. In that context, the
importance of validating sets of molecules present in the circula-
tion as biomarkers of low-grade inﬂammation has been empha-
sized (Calder et al., 2013). At the same time, the predictive value
tentatively attributed by the authors of this review to these sets
of inﬂammatory markers, illustrates the gap with the position of
regulatory authorities. The present review further highlights this
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A
Figure 3. Distribution of the study results labeled as “anti-inﬂammatory”, “no effect”, and “pro-inﬂammatory” for the entire data set composed of 78 study
results. (A) Number of study results labeled as “anti-inﬂammatory”, “no effect”, “pro-inﬂammatory” based on the initial grading deﬁned in Table 2. (B) Distribu-
tion of the Inﬂammatory Score. The color code indicates the direction of change of the inﬂammatory marker, i.e., signiﬁcant anti-inﬂammatory change (black
bars), no signiﬁcant change (grey bars), and signiﬁcant pro-inﬂammatory change (white bars).
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with convincingly addressing clinical outcomes, as described by
the descriptor “Clinical evidence” in Tables 3–5, are unsurpris-
ingly scarce.
Validation issues are raised by new analytical technologies
that now allow researchers to quantitate large sets of inﬂamma-
tory markers in a single measurement (Liu et al., 2005; Breen
et al., 2011; Thompson et al., 2012). Although these analytical
issues were not discussed in the set of human trials reviewed,
particular care should be taken in the future to better character-
ize the performance of these tests.
Regulatory authorities clearly highlight the importance of
characterizing the food products investigated in human trials
in their guidance for the authorization of health claims (EFSA
Panel on Dietetic Products Nutrition and Allergies, 2011; FDA
Ofﬁce of Nutrition Labeling and Dietary Supplements, 2009).
However, the studies reported in this review give little emphasis
on the characterization of the dairy products investigated, as
Table 6. Inﬂammatory Score for the impact of dairy products on humans.
N Q11 Median Q31 Mean p2 p3
All data
ALL study results 78 0 0 6 1.4 0.009
Subject category
HEALTH 37 ¡3.2 0 6 1.7 0.017 0.083
MET 24 0 4.5 7.5 3.9 0.001
GIT 8 ¡5.5 ¡2.5 0 ¡3.1 0.066
HYPER 6 ¡6 ¡6 ¡6 ¡5.5 0.034
OTHER 3 0 0 6.75 3.0 0.317
Product category
High-fat 35 ¡2.25 0 6 1.7 0.017 0.084
Low-fat 20 0 4.5 7.5 4.2 0.001
Non-fermented 33 0 0 6 1.8 0.108 0.845
Fermented 16 0 0 7 2.4 0.037
1Abbreviations: Q1, ﬁrst quartile; Q3: third quartile.
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Figure 4. Distribution of the study results labeled as “anti-inﬂammatory”, “no
effect”, and “pro-inﬂammatory” among the subject categories. Subject categories:
HEALTH, healthy subjects; MET, subject with metabolic disorders including obesity;
GIT, subjects with gastrointestinal disorders; HYPER, subjects with hypersensitivity,
including allergy, to milk products. The color code indicates the direction of
change of the inﬂammatory marker, i.e., signiﬁcant anti-inﬂammatory change
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Fat content of dairy products
Figure 5. Distribution of the study results labeled as “anti-inﬂammatory”, “no
effect”, and “pro-inﬂammatory” among the dairy product categories “high-fat”
and “low-fat”. The color code indicates the direction of change of the inﬂamma-
tory marker, i.e., signiﬁcant anti-inﬂammatory change (black bars), no signiﬁcant
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Fermentation status of dairy products
Figure 6. Distribution of the study results labeled as “anti-inﬂammatory”, “no
effect”, and “pro-inﬂammatory” among the dairy product categories “fermented”
and “non-fermented”. The color code indicates the direction of change of the
inﬂammatory marker, i.e., signiﬁcant anti-inﬂammatory change (black bars), no sig-
niﬁcant change (grey bars), and signiﬁcant pro-inﬂammatory change (white bars).
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illustrated by a range of uncharacterized descriptors in
Tables 3–5 (e.g., identiﬁcation of bioactive nutrients, bioavail-
ability data, dose-response effects, sustainability of the effect of
the food product over time). In particular, integrating the vari-
able ‘dose’ into study designs could allow researchers to draw
a causal relationship between the food investigated and the
physiological response measured in humans (Schwander
et al., 2014). Also, although dozens of nutrients with immuno-
modulatory activity have been proposed in the literature (Bal-
lard and Morrow, 2013), the bioactive nutrients potentially
modulating inﬂammation in the reviewed studies, remain
largely unknown even considering animal studies. The major
reason for this gap is clearly inherent to the complex molecular
composition of food. In light of the importance of the food
matrix on the properties of bioactive nutrients, we endorse that
food and nutrition research should shift its focus from the char-
acterization of the nutritional and immunomodulatory proper-
ties of isolated nutrients to the characterization of foods, meals,
and even dietary patterns.
The scientiﬁc basis for claims on bioactive food and
nutrients established by national regulatory authorities is not
harmonized, thereby hindering internationally harmonized
market access (Aggett et al., 2012). To date, a very high number
of requested health claims (more than 80%) have been rejected
by the EFSA’s NDA Panel, who underlined the need to identify
the molecule(s) responsible of the claimed effect, and their
mechanisms of action. The mechanisms of action of bioactives
are usually studied in vitro, whereas in vivo studies are very
often focused on demonstrating an effect on speciﬁc endpoints,
without considering the underlying mechanisms. Evidence of
the anti-inﬂammatory effectiveness of dairy components could
be retrieved from in vitro studies, but they were not considered
in this review for a speciﬁc reason, i.e., bioactive components
are just one part of food, embedded in a very complex matrix.
Cell supplementation in in vitro studies, as well as intervention
studies administering bioactives as pure compounds assume
that there are no confounding effects related to the food matrix.
The food matrix, as well as food processing (Bordoni et al.,
2011) can, indeed modify the digestibility and bioavailability of
bioactive compounds, thus introducing a fundamental bias
when translating in vitro data to humans. The ideal in vitro
study should thus digest food in a static or dynamic model of
digestion, have the digested nutrients transported through an
intestinal cellular layer mimicking the gastrointestinal barrier,
ideally with a model integrating the gut microbiota, and ﬁnally
measure the ability of the absorbed nutrients to modulate
inﬂammation. Such integrated in vitro models have not yet
been successfully developed, although ﬁrst steps in that direc-
tion have already been taken (Vergeres et al., 2012). Meanwhile,
the COST action FA1005 ‘Improving health properties of food
by sharing our knowledge on the digestive process’ (INFOGEST)
has published an harmonized protocol of in vitro digestion
(Minekus et al., 2014). To perform in vitro digestion prior to in
vitro studies will help to bypass the enormous, and unscientiﬁc,
gap in our knowledge related to the assumption, without any
demonstration, that the in vivo effects of foods are related to
the mechanisms of action observed in vitro supplementing cells
with pure molecules. In vitro studies supplementing cells with
digested food can mimic in a closer way the in vivo effects and
underlying mechanism of actions of food bioactives, thus
evidencing the cause-effect relationship as requested by the
body authorities.
Strengths and limitations of the IS
The literature focusing on the impact of dairy products on
inﬂammatory processes in humans revealed a very heteroge-
neous methodological landscape. The IS was therefore deﬁned
in order to take these limitations into account as follows:
Inﬂammation is a complex phenomenon that cannot be
described by a single biomarker (Calder et al., 2013). Indeed, more
than ﬁfty inﬂammatory markers were reported in the pool of the
52 human studies reviewed. The data consisted of cellular markers
of inﬂammation and measures of tissue inﬁltration, but the major-
ity of studies concentrated on a few soluble circulatory cytokines.
Furthermore, the number of markers measured in each study var-
ied from one to more than ten. These points all raised the issue of
the weighting of each study result in this heterogeneous environ-
ment. For the sake of simplicity, and to avoid over-interpreting the
data, we decided to (i) rate each of the inﬂammatory markers listed
in Table 1 at the same level and (ii) to increase the IS by one unit in
cases in which changes in the concentration of more than one
inﬂammatory markers were pointing in the same direction (see
point 5 in Table 2). Note, however, that the IS was not upgraded
by additional grades for studies in which more than two inﬂam-
matory markers were concordantly changed as this would have
given too much weight to this criterion compared to the ten other
criteria presented in Table 2.
As milk is amenable to a wide range of technological trans-
formations and important in human diets, a large spectrum of
dairy products was investigated in the 52 reviewed studies. As
each of these products may differently modulate inﬂammation,
we addressed this issue by deﬁning a limited range of product
categories in which the data could be stratiﬁed and analyzed
(low-fat vs. high fat; fermented vs. non-fermented).
The health status of the subjects enrolled in the 52 studies
was quite diverse, reﬂecting the generic importance of inﬂam-
matory processes in modulating human health and disease.
The clinical indications targeted by these studies were conse-
quently heterogeneous and we therefore classiﬁed the study
results according to a limited, but clinically meaningful, set of
subject categories (HEALTH, MET, GIT, HYPER).
Given the relative paucity of high-quality studies on the topic of
dairy and inﬂammation, we chose an inclusive strategy which
means that we considered all available publications on dairy and
systemic inﬂammation, including randomized controlled trials,
cross-over design trials and longitudinal cohort studies. This
approach enabled us to analyze data from studies per se not con-
sidered in systemic reviews and we could thus provide a wide over-
view of studies dealing with dairy and inﬂammation. The
downside of this strategy is that some studies of low quality, small
sample size and short duration, were included in this review.
The last issue that became evident during the reviewing pro-
cess, is the usage of dairy products as controls in human studies
actually aiming at investigating the ability of other food prod-
ucts to modulate inﬂammatory processes. This phenomenon
was particularly the case for clinical studies using the milk
matrix to supplement the test meals with bioactive
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components. Given the potential bioactivity of dairy products,
we decided to also evaluate their properties even when used as
control products, although this might pose the risk of mislead-
ing information when comparing data against baseline within
randomized groups (Bland and Altman, 2011).
Conclusions
We have established the IS as a new tool to conduct a quantita-
tive evaluation of human studies investigating the impact of
dairy products on inﬂammation. Taken together, our review
suggests that dairy products, in particular fermented products,
have anti-inﬂammatory properties in humans not suffering
from allergy to milk, in particular in subjects with metabolic
disorders. As the clinical relevance of inﬂammatory markers is
currently debated among researchers and regulatory authori-
ties, the translation of these ﬁndings into dietary guidelines
remains to be clariﬁed.
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